title: Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses.
abstract: Elevations of plasma cholesterol and/or triglycerides, and the prevalence of small, dense LDL particles remarkably increase coronary risk in patients with familial combined hyperlipidemia (FCHL). A total of 14 FCHL patients were studied, to investigate the ability of Omacor, a drug containing the n-3 fatty acids eicosapentaenoic and docosahexaenoic acid (EPA and DHA), to favorably correct plasma lipid/lipoprotein levels and LDL particle distribution. The patients received four capsules daily of Omacor (providing 3.4 g EPA+DHA per day) or placebo for 8 weeks in a randomized, double-blind, cross-over study. Omacor significantly lowered plasma triglycerides and VLDL-cholesterol levels, by 27 and 18%, respectively. Total cholesterol did not change but LDL-cholesterol and apolipoprotein B (apoB) concentrations increased by 21 and 6%. As expected, LDL particles were small (diameter=24.9+/-0.3 nm) and apoB-rich (LDL-cholesterol/apoB ratio=1.27+/-0.26) in the selected subjects. After Omacor treatment LDL became enriched in cholesterol (LDL-cholesterol/apoB ratio=1.40+/-0.17), mainly cholesteryl esters, indicating accumulation in plasma of more buoyant and core enriched LDL particles. Indeed, the separation of LDL subclasses by rate zonal ultracentrifugation showed an increase of the plasma concentration of IDL and of the more buoyant, fast floating LDL-1 and LDL-2 subclasses after Omacor, with a parallel decrease in the concentration of the denser, slow floating LDL-3 subclass. However, the average LDL size did not change after Omacor (25.0+/-0.3 nm). The resistance of the small LDL pattern to drug-induced modifications implies that a maximal lipid-lowering effect must be achieved to reduce coronary risk in FCHL patients.
authors.affiliation: Center E. Grossi Paoletti, Institute of Pharmacological Sciences, University of Milano, via Balzaretti 9, 20133, Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Calabresi
authors.forename: D
authors.initials: D
authors.lastname: Donati
authors.forename: F
authors.initials: F
authors.lastname: Pazzucconi
authors.forename: C R
authors.initials: CR
authors.lastname: Sirtori
authors.forename: G
authors.initials: G
authors.lastname: Franceschini
mesh_terms: D000328:Adult; D002784:Cholesterol / Q000097:blood / Q000145:classification; D018592:Cross-Over Studies; D004281:Docosahexaenoic Acids / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006950:Hyperlipidemia, Familial Combined / Q000097:blood* / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood* / Q000145:classification; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D004338:Drug Combinations; D008055:Lipids; D008077:Lipoproteins, LDL; D014280:Triglycerides; D004281:Docosahexaenoic Acids; D002784:Cholesterol; D015118:Eicosapentaenoic Acid; C405603:Omacor